Valuation: Astellas Pharma Inc.

Market Cap 4,224B 26.53B 22.98B 21.53B 19.64B 36.93B 2,530B 37.49B 253B 99B 1,267B 99.6B 97.43B P/E 2027 *
11.8x
P/E 2028 * 12.4x
Enterprise Value 4,235B 26.6B 23.04B 21.59B 19.69B 37.02B 2,537B 37.59B 254B 99.26B 1,270B 99.86B 97.69B EV / Sales 2027 *
1.85x
EV / Sales 2028 * 1.81x
Free-Float
98.88%
Yield 2027 *
3.41%
Yield 2028 * 3.52%
1 day-1.21%
1 week+1.70%
Current month+5.70%
1 month+9.74%
3 months-2.08%
6 months-7.29%
Current year+11.20%
1 week 2,243.5
Extreme 2243.5
2,377
1 month 2,110
Extreme 2110
2,377
Current year 2,041
Extreme 2041
2,717
1 year 1,557.5
Extreme 1557.5
2,717
3 years 1,243.5
Extreme 1243.5
2,717
5 years 1,243.5
Extreme 1243.5
2,717
10 years 1,243.5
Extreme 1243.5
2,717
Manager TitleAgeSince
Chief Executive Officer 63 09/02/2023
Director of Finance/CFO 54 31/10/2023
Compliance Officer - 31/03/2025
Director TitleAgeSince
Chairman 66 09/02/2023
Director/Board Member 63 31/05/2019
Director/Board Member 58 31/05/2023
Change 5-day change 1-year change 3-year change Capi.($)
-1.21%+1.70%+40.08%+4.65% 26.53B
-0.19%+2.79%+85.49%+127.72% 1,088B
-0.36%+1.30%+49.25%+50.10% 629B
+1.26%+3.52%+25.30%+65.79% 440B
-1.11%-0.49%+45.33%+37.02% 359B
-0.32%-1.02%+27.05%+36.27% 291B
-0.44%-1.64%+1.85%+4.88% 245B
+0.45%+3.11%+44.28%+59.96% 225B
-0.57%+1.31%-8.73%-51.97% 204B
+0.89%+4.32%+13.63%+70.96% 168B
Average -0.17%+2.06%+32.36%+40.54% 367.57B
Weighted average by Cap. -0.13%+1.98%+46.58%+65.11%

Financials

2027 *2028 *
Net sales 2,288B 14.37B 12.45B 11.67B 10.64B 20B 1,371B 20.31B 137B 53.63B 686B 53.96B 52.78B 2,101B 13.19B 11.43B 10.71B 9.77B 18.37B 1,258B 18.65B 126B 49.24B 630B 49.54B 48.46B
Net income 343B 2.16B 1.87B 1.75B 1.6B 3B 206B 3.05B 20.59B 8.05B 103B 8.1B 7.92B 324B 2.03B 1.76B 1.65B 1.51B 2.83B 194B 2.88B 19.43B 7.59B 97.17B 7.64B 7.47B
Net Debt 11.12B 69.85M 60.52M 56.7M 51.72M 97.23M 6.66B 98.72M 667M 261M 3.34B 262M 257M -418B -2.62B -2.27B -2.13B -1.94B -3.65B -250B -3.71B -25.04B -9.79B -125B -9.85B -9.63B
Logo Astellas Pharma Inc.
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Employees
14,099
Date Price Change Volume
13/08/26 JP¥2,327.50 -1.21% 4,696,600
12/08/26 JP¥2,356.00 -0.30% 6,164,000
10/08/26 JP¥2,363.00 +1.55% 6,287,500
07/08/26 JP¥2,327.00 +1.68% 8,001,800
06/08/26 JP¥2,288.50 +6.00% 10,352,900
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
2,356.00JPY
Average target price
2,413.08JPY
Spread / Average Target
+2.42%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4503 Stock